Elevance Health delivered robust first-quarter 2026 results, reporting adjusted earnings per share of $12.58, surpassing analysts' expectations by 17.8%. This performance has led Bank of America to upgrade the stock from Neutral to Buy, with a target price of $435. Despite a recent share decline of 13.91% over the past year, Elevance is currently trading at a discount to the broader market and shows a one-month return of 21.65%, although it faces challenges with projected Medicaid margins of -1.75%.
“Elevance Health · delivered year-on-year revenue growth · 1.5%”
“BofA · upgraded · Elevance Health (ELV) · Buy from Neutral”
“Bank of America · upgraded · Elevance Health · Buy from Neutral with a price objective of $435”
“Elevance · is guiding to · Medicaid margins · -1.75%”
“Elevance Health and Humana · closed · up · +3%”
“BofA Securities · upgrades · Elevance Health”
“Elevance Health · serves · approximately 104 million consumers · through a diverse portfolio of solutions”
“Elevance Health · beat · analysts' expectations · by 2.4%”
“Elevance Health · reported first-quarter 2026 adjusted earnings per share of · $12.58 · surpassed the Zacks Consensus Estimate by 17.8%”
“Bank of America · upgraded · Elevance Health · Buy from Neutral”
“BofA · raised price objective for Elevance Health · price objective · $435”
“Elevance Health · reported · first-quarter 2026 adjusted earnings per share · $12.58”
